Global Immune Check Point Inhibitors Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Immune Check Point Inhibitors Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 CLTA-4 Inhibitors
  • 1.4.3 PD-1 & PD-L1 Inhibitor
• 1.5 Market by Application
  • 1.5.1 Global Immune Check Point Inhibitors Market Share by Application (2014-2025)
  • 1.5.2 Lung Cancer
  • 1.5.3 Blood Cancer
  • 1.5.4 Renal Cancer
  • 1.5.5 Bladder Cancer
  • 1.5.6 Melanoma
  • 1.5.7 Hodgkin Lymphoma
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Immune Check Point Inhibitors Market Size
• 2.2 Immune Check Point Inhibitors Growth Trends by Regions
  • 2.2.1 Immune Check Point Inhibitors Market Size by Regions (2014-2025)
  • 2.2.2 Immune Check Point Inhibitors Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Immune Check Point Inhibitors Market Size by Manufacturers
  • 3.1.1 Global Immune Check Point Inhibitors Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Immune Check Point Inhibitors Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Immune Check Point Inhibitors Market Concentration Ratio (CR5 and HHI)
• 3.2 Immune Check Point Inhibitors Key Players Head office and Area Served
• 3.3 Key Players Immune Check Point Inhibitors Product/Solution/Service
• 3.4 Date of Enter into Immune Check Point Inhibitors Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Immune Check Point Inhibitors Market Size by Type (2014-2019)
• 4.2 Global Immune Check Point Inhibitors Market Size by Application (2014-2019)

5 United States

• 5.1 United States Immune Check Point Inhibitors Market Size (2014-2019)
• 5.2 Immune Check Point Inhibitors Key Players in United States
• 5.3 United States Immune Check Point Inhibitors Market Size by Type
• 5.4 United States Immune Check Point Inhibitors Market Size by Application

6 Europe

• 6.1 Europe Immune Check Point Inhibitors Market Size (2014-2019)
• 6.2 Immune Check Point Inhibitors Key Players in Europe
• 6.3 Europe Immune Check Point Inhibitors Market Size by Type
• 6.4 Europe Immune Check Point Inhibitors Market Size by Application

7 China

• 7.1 China Immune Check Point Inhibitors Market Size (2014-2019)
• 7.2 Immune Check Point Inhibitors Key Players in China
• 7.3 China Immune Check Point Inhibitors Market Size by Type
• 7.4 China Immune Check Point Inhibitors Market Size by Application

8 Japan

• 8.1 Japan Immune Check Point Inhibitors Market Size (2014-2019)
• 8.2 Immune Check Point Inhibitors Key Players in Japan
• 8.3 Japan Immune Check Point Inhibitors Market Size by Type
• 8.4 Japan Immune Check Point Inhibitors Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Immune Check Point Inhibitors Market Size (2014-2019)
• 9.2 Immune Check Point Inhibitors Key Players in Southeast Asia
• 9.3 Southeast Asia Immune Check Point Inhibitors Market Size by Type
• 9.4 Southeast Asia Immune Check Point Inhibitors Market Size by Application

10 India

• 10.1 India Immune Check Point Inhibitors Market Size (2014-2019)
• 10.2 Immune Check Point Inhibitors Key Players in India
• 10.3 India Immune Check Point Inhibitors Market Size by Type
• 10.4 India Immune Check Point Inhibitors Market Size by Application

11 Central & South America

• 11.1 Central & South America Immune Check Point Inhibitors Market Size (2014-2019)
• 11.2 Immune Check Point Inhibitors Key Players in Central & South America
• 11.3 Central & South America Immune Check Point Inhibitors Market Size by Type
• 11.4 Central & South America Immune Check Point Inhibitors Market Size by Application

12 International Players Profiles

• 12.1 Bristol-Myers Squibb Company
  • 12.1.1 Bristol-Myers Squibb Company Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Immune Check Point Inhibitors Introduction
  • 12.1.4 Bristol-Myers Squibb Company Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.1.5 Bristol-Myers Squibb Company Recent Development
• 12.2 AstraZeneca plc
  • 12.2.1 AstraZeneca plc Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Immune Check Point Inhibitors Introduction
  • 12.2.4 AstraZeneca plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.2.5 AstraZeneca plc Recent Development
• 12.3 Merck & Co
  • 12.3.1 Merck & Co Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Immune Check Point Inhibitors Introduction
  • 12.3.4 Merck & Co Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.3.5 Merck & Co Recent Development
• 12.4 Pfizer, Inc
  • 12.4.1 Pfizer, Inc Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Immune Check Point Inhibitors Introduction
  • 12.4.4 Pfizer, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.4.5 Pfizer, Inc Recent Development
• 12.5 F. Hoffmann-La Roche Ltd
  • 12.5.1 F. Hoffmann-La Roche Ltd Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Immune Check Point Inhibitors Introduction
  • 12.5.4 F. Hoffmann-La Roche Ltd Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.5.5 F. Hoffmann-La Roche Ltd Recent Development
• 12.6 Incyte Corporation
  • 12.6.1 Incyte Corporation Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Immune Check Point Inhibitors Introduction
  • 12.6.4 Incyte Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.6.5 Incyte Corporation Recent Development
• 12.7 NewLink Genetics Corporation
  • 12.7.1 NewLink Genetics Corporation Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Immune Check Point Inhibitors Introduction
  • 12.7.4 NewLink Genetics Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.7.5 NewLink Genetics Corporation Recent Development
• 12.8 Celldex Therapeutics, Inc
  • 12.8.1 Celldex Therapeutics, Inc Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Immune Check Point Inhibitors Introduction
  • 12.8.4 Celldex Therapeutics, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.8.5 Celldex Therapeutics, Inc Recent Development
• 12.9 GlaxoSmithKline plc
  • 12.9.1 GlaxoSmithKline plc Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Immune Check Point Inhibitors Introduction
  • 12.9.4 GlaxoSmithKline plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.9.5 GlaxoSmithKline plc Recent Development
• 12.10 Seattle Genetics, Inc.
  • 12.10.1 Seattle Genetics, Inc. Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Immune Check Point Inhibitors Introduction
  • 12.10.4 Seattle Genetics, Inc. Revenue in Immune Check Point Inhibitors Business (2014-2019)
  • 12.10.5 Seattle Genetics, Inc. Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer